Colour Star Technology [NASDAQ: CSCW]
Colour Star Technology [NASDAQ: CSCW] is a top performer this morning and is up by over 51% pre-market. This follows the company’s announcement that it will be launching a series of interactive events that will be aired live. These events will feature the company’s growing group of Star Teachers. It is in line with the firm’s celebration of upgrading its Colour World App. The first event will feature the establishment’s “Star Teacher” Julaiti, a 20-year-old musician who has grown in popularity following his top hit that attained a top 15 finish on “Super Boy 2017”. This event will present users of the Colour World App with a rare opportunity to interact with this famed musician.
Altimmune, Inc [NASDAQ: ALT]
Altimmune, Inc [NASDAQ: ALT] is in the green pre-market too. In its bid to manufacture a COVID-19 vaccine, announced yesterday the launch of its pre-clinical trials of its single-dose, intranasal COVID-19 vaccine called AdCOVID. This vaccine is based on the firm’s adenovirus-based intranasal platform the expresses the receptor-binding domain (RBD) of the protein found in SARS-CoV-2. RBD is important as a preventative measure that will keep vaccinated individuals with a history of prior infection from spreading the virus. The virus has an advantage over many other available vaccines thanks to its single-dose effectiveness, intranasal administration, broad immune activation, and the ease with which it can be stored and transported. Altimmune worked in collaboration with the University of Alabama expanding on its earlier preclinical data. This is a big deal and could see the stock rally all through the day.
Auris Medical Holding Ltd [NASDAQ: EARS]
Auris Medical Holding Ltd [NASDAQ: EARS] is in the green pre-market and is up by over 88% without any major news. The company that has a lead product candidate for acute vertigo had positive progress last month. The rally also comes more than a month after the company announced its business update financial results for the fiscal year ended 2020. Auris Medical’s founder, CEO, and Chairman said that they have had significant milestones with their intranasal betahistine program. They have reported positive results in the last two clinical trials. The two trials AM-125 and AM-201 showed therapeutic potential in the development of a drug-free nasal spray against airborne diseases. There is a strong need for protection against airborne diseases as shown by the ongoing COVID-19 pandemic. The biopharmaceutical company hopes to develop such protection with its going trials.